Services
Analytical Services


CreaGen provides a broad range of analytical support services to drug discovery companies. CreaGen’s state-of-the-art analytical laboratory houses a Varian 300 MHz multinuclear NMR instrument, and a Waters Micromass Quattro Ultima Mass Spectrometer coupled to a Shimadzu LC-10AD VP high pressure liquid chromatography system coupled with a Sedex 55 ELSD detector for performing LC/MS analyses.

Several Agilent and Waters stand-alone HPLC systems are also available for performing preparative scale purifications, separations and analyzing sample mixtures.

Additional services include identification of impurities, structural elucidation, HPLC method development, NMR interpretation and Certificate of Analyses for any compound that will be utilized in animal studies. We have a dedicated analytical chemistry staff that closely collaborates with organic chemists to solve the most difficult and complex analytical problems of our customers.



Please contact the analytical chemistry coordinator for prices and additional analytical chemistry services.

 
News
  CreaGen Inc. makes into the 2018 list of major players in CRO industry
https://www.businesswire.com/news/home/20180412005808/en/Outsourcing-Drug-Discovery-Contract-Research-Organization-CRO https://themobileherald.com/contract-research-organization-market-industry-growth-and-forecast-analysis-report-till-2024/24870/ https://www.businesswire.com/news/home/20180412005808/en/Outsourcing-Drug-Discovery-Contract-Research-Organization-CRO   more...
    7th Advances In Chemical Sciences Symposium: May 4th, 2018
The Seventh Annual Advances in Chemical Sciences Symposium Royal Sonesta Hotel Cambridge, MA: May 4th, 2018 A day-long symposium focused on Medicinal Chemistry, Organic Synthesis, and Methodology, featuring eminent scientists from industry and academia. Speakers: Professor Richard R. Schrock (MIT): “TBA” Professor Dale L. Boger (Scripps Research Institute): “Redesign of Vancomycin for Resistant Bacteria” Professor Laura Kiessling (MIT): “TBA” Dr. Sue Ashwell (Forma Therapeutics): “Discovery and Optimization of a Novel Series of Inhibitors of mt-IDH1” Dr. Michael Hoemann (Abbvie): “Discovery and Optimization of Spleen Tyrosine Kinase Inhibitors for Immunological Diseases” Dr. Frank Salituro (Sage Therapeutics): “Discovery and Clinical Development of SAGE-217: A Next Generation Neuroactive Steroid Positive Allosteric Modulator of the (GABA)A Receptor” Plus: Vendor Exhibition Hall and Networking Reception   more...
 
 
Home  |  About Us  |  Services  |  Products  |  R&D  |  News  |  Careers  |  Contact us Copyright © 2013 CreaGen Biosciences Inc. All rights reserved.